TBPH FY 2019 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$73M+21.6% YoY

Gross Profit

$73M100.0% margin

Operating Income

-$252M-343.1% margin

Net Income

-$236M-322.1% margin

EPS (Diluted)

$-4.25

Cash Flow

Operating Cash Flow

-$238M

Free Cash Flow

-$241M

Stock-Based Comp.

$60M

Balance Sheet

Total Assets

$409M

Total Liabilities

$633M

Stockholders' Equity

-$224M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$60M	+21.6%
Gross Profit	$73M	$60M	+23.1%
Operating Income	-$252M	-$239M	-5.5%
Net Income	-$236M	-$216M	-9.7%